Li Ning Company Limited (HKG:2331)

Intra-Cellular Therapies Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	7,499	5,444	7,382	14,745	7,187
Short-Term Investments	8,264	3,494	643.32	400.86	-
Cash & Short-Term Investments	15,763	8,938	8,026	15,146	7,187
Cash Growth	76.37%	11.36%	-47.01%	110.74%	20.56%
Accounts Receivable	1,005	1,206	1,020	902.86	658.8
Other Receivables	784.04	591.94	602.26	606.04	65.2
Receivables	1,789	1,797	1,623	1,509	723.99
Inventory	2,598	2,493	2,428	1,773	1,346
Prepaid Expenses	74.97	95.27	105.72	109.22	-
Other Current Assets	303.46	329.46	212.99	135.18	519.99
Total Current Assets	20,528	13,653	12,395	18,672	9,777
Property, Plant & Equipment	6,187	6,308	5,257	2,959	2,131
Long-Term Investments	4,572	11,072	12,567	4,772	1,356
Goodwill	72.39	95.92	107.38	107.38	103.08
Other Intangible Assets	313.21	279.6	268.63	242.88	254.04
Long-Term Deferred Tax Assets	949.42	800.96	693.4	707.58	590.64
Other Long-Term Assets	3,086	1,998	2,358	2,814	382.43
Total Assets	35,708	34,208	33,647	30,275	14,594
Accounts Payable	1,625	1,790	1,584	1,599	1,227
Accrued Expenses	2,203	1,802	2,078	2,313	1,385
Current Portion of Leases	551.61	716.67	667.76	366.97	360.9
Current Income Taxes Payable	950.35	915.28	1,037	1,308	591.86
Current Unearned Revenue	368.52	552.54	252.09	345.84	286.13
Other Current Liabilities	1,887	1,492	1,622	1,771	1,164
Total Current Liabilities	7,586	7,268	7,241	7,704	5,015
Long-Term Leases	1,385	1,825	1,474	956.48	688.64
Long-Term Unearned Revenue	48.99	71.59	65.59	62.52	64.44
Long-Term Deferred Tax Liabilities	568.75	627.23	518.73	426.87	102.74
Other Long-Term Liabilities	16.5	8.58	15.53	21	33.58
Total Liabilities	9,605	9,801	9,315	9,171	5,904
Common Stock	235.85	239.55	240.32	238.76	228.29
Additional Paid-In Capital	9,011	10,173	11,581	12,637	4,038
Retained Earnings	16,123	14,081	11,848	7,785	4,289
Treasury Stock	-290.9	-1,038	-180.84	-	-
Comprehensive Income & Other	1,024	951.77	840.89	441	131.98
Total Common Equity	26,104	24,407	24,329	21,102	8,687
Minority Interest	-	-	2.5	2.56	2.55
Shareholders' Equity	26,104	24,407	24,332	21,104	8,689
Total Liabilities & Equity	35,708	34,208	33,647	30,275	14,594
Total Debt	1,936	2,542	2,142	1,323	1,050
Net Cash (Debt)	13,827	6,396	5,884	13,822	6,138
Net Cash Growth	116.19%	8.70%	-57.43%	125.21%	21.12%
Net Cash Per Share	5.35	2.46	2.23	5.44	2.44
Filing Date Shares Outstanding	2,575	2,574	2,627	2,612	2,474
Total Common Shares Outstanding	2,575	2,574	2,627	2,612	2,474
Working Capital	12,942	6,385	5,154	10,968	4,761
Book Value Per Share	10.14	9.48	9.26	8.08	3.51
Tangible Book Value	25,718	24,031	23,953	20,751	8,330
Tangible Book Value Per Share	9.99	9.34	9.12	7.94	3.37
Buildings	3,301	1,893	763.15	831.54	524.51
Machinery	1,246	1,101	827.34	731.99	613.01
Construction In Progress	966.75	1,379	1,496	93.59	43.18
Leasehold Improvements	2,776	3,121	2,387	1,924	1,492

Updated Sep 4, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.